Psychopharmacology

Review the highlights from last week's meeting of the American Society for Clinical Psychopharmacology.

Phase 3 at-home data show sublingual dexmedetomidine cuts severe agitation in bipolar disorder and schizophrenia, supporting FDA label expansion.

Check out the pipeline updates from May!

Real-world claims show opioids remain common in fibromyalgia despite guidance, highlighting safety concerns and interest in FDA-approved non-opioid option Tonmya.

At the 2026 ASCP Annual Meeting, Eric Konofal, MD, PhD, argued that sleep assessment should become a routine part of ADHD evaluation and treatment.

Expert psychiatrists share new ASCP deprescribing guidance, tackling overprescribing, primary-care challenges, and practical tapering strategies to improve safer, patient-centered mental health care.

New real-world data in obese, antidepressant-naive patients with MDD shows bupropion edging SSRIs on remission, though rates stay low.

Investigational depression drugs target SIRT6 epigenetics, histamine H3, and AMPA.

APA session probes ADHD stimulant prescribing, contrasts population studies with RCTs, and explores education and brain effects.

Researchers at the ASCP Annual Meeting reported on how impaired brain insulin signaling may predict worsening depression severity and the links between metabolism and mood.

AI adoption in psychiatry and emerging psychedelic therapies are among the most anticipated topics at ASCP 2026, according to Benjamin Brody, MD.

David W. Goodman, MD, discusses the new ASCP consensus recommendations on when clinicians should consider deprescribing stimulants as part of good ADHD care.

John J. Miller, MD, Psychiatric Times editor in chief, looks forward to learning and sharing the late-breaking science, expert interviews, and new podcast conversations in psychopharmacology.

Learn how to spot bipolar mixed features, avoid antidepressant pitfalls, and choose evidence-based antipsychotics.

Olanzapine-samidorphan keeps olanzapine efficacy yet limits weight gain, boosts negative symptoms, and cuts ER visits in real-world care.

Learn more about strategies for deprescribing, and the importance of finding the most effective medication possible.

Learn more about medication use in pregnancy and postpartum, including risks and benefit analysis.

Learn why adult ADHD often hides behind anxiety or depression, how childhood history and family risk guide diagnosis, and why stimulants still matter.

Guidance on psychotropic meds in pregnancy: personalize decisions, coordinate care, and plan early to prevent postpartum relapse.

GLP-1 drugs like semaglutide may curb alcohol and opioid cravings, as trials expand, combos emerge, and interaction risks surface.

Planning for prevention of perinatal psychiatric relapse with safer medication options.

Discover APA sessions on OCD therapies, gut-brain microbiome insights, AI, sports psychiatry, and geriatric updates from top clinicians.

Expert shares the use of liquid formulation ADHD medication and how to discuss with patients.

Massive Lancet meta-analysis suggests most use of antidepressants while pregnant does not raise autism or ADHD risk after confounders, easing treatment decisions.

Lisdexamfetamine liquid targets ADHD and binge eating, easing pill-swallowing and sensory barriers to improve adherence.